BioTech Health X
  • BioTech News
  • BioTech CEO Interviews
  • BioTech Events
  • BioTech Company Directory
  • Contact Us
Archives
  • August 2023
  • July 2023
  • May 2023
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • December 2021
  • November 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2017
  • March 2014
BioTech Health X
  • BioTech News
  • BioTech CEO Interviews
  • BioTech Events
  • BioTech Company Directory
  • Contact Us
Subscribe

Browsing Tag

Vivo Capital

1 post

Vivo Capital is an investment firm focused on the healthcare industry. Vivo was formed in 1996 and is currently investing in companies from its $1.4B Vivo Capital Fund IX into promising private healthcare companies and from its $635M Vivo Opportunity Fund into promising public healthcare companies.

The global healthcare investment firm has approximately $5.8 Billion in assets under their management with an investment history of over 25 years.

Vivo has three fund vehicles including Private Equity, Public Equity and Venture Capital.

Aerobiotix Announces Raise of $25M Growth Equity Financing Led by Healthcare Investment Firm Vivo Capital

Biotech NewsAerobiotix Announces Raise of $25M Growth Equity Financing Led by Healthcare Investment Firm Vivo Capital

  • Jak Thomson
  • May 6, 2021
Aerobiotix, a pioneer in airborne infection control products that provide real-time, in room solutions for hospitals, ASCs, long…
0 Shares
0
0
0
0
0
0
0
Recent Posts
  • Alterome Therapeutics Strengthens Leadership Team with Appointment of Renowned Oncologist Dr. Andrew S. Chi as Chief Medical Officer
  • Exclusive: Cel-Sci CEO Geert Kersten Talks Multikine, FDA Approval, CVM Future
  • 11/19/21
  • Welcome To BioTech Health X
  • Recent Report Highlights Success in FDA Subgroup Approval & Treatment Arm Data
Recent Comments
  • Thomas Shentz on Cellarity Expands Leadership Team to Continue Evolution of Breakthrough Platform to Encode Biology and Purposefully Create New Drugs
  • Tomasz Michałowski on Exclusive: Cel-Sci CEO Geert Kersten Talks Multikine, FDA Approval, CVM Future
  • Presenters Announced for 2021 William Blair Biotech Conference • BioTech Health X on William Blair Biotech Focus Conference 2021 Panel Schedule
Featured Posts
    • August 23, 2023
    Alterome Therapeutics Strengthens Leadership Team with Appointment of Renowned Oncologist Dr. Andrew S. Chi as Chief Medical Officer
    • July 14, 2023
    Exclusive: Cel-Sci CEO Geert Kersten Talks Multikine, FDA Approval, CVM Future
    Exclusive Cel-Sci CEO Geert Kersten Talks Multikine, FDA Approval, CVM Future
    • May 30, 2023
    11/19/21
    • May 26, 2023
    Welcome To BioTech Health X
    Welcome To BioTech Health X
    • May 9, 2023
    Recent Report Highlights Success in FDA Subgroup Approval & Treatment Arm Data
    Recent Report Highlights Success in FDA Subgroup Approval & Treatment Arm Data
Recent Posts
  • Virios-Therapeutics-Stock-Plunges-70-on-Fibromyalgia-Clinical-Trial-Failure-Results
    Virios Therapeutics Stock Plunges 70% on Fibromyalgia Clinical Trial Failure Results
    • September 19, 2022
  • CEL-SCI Multikine Phase 3 Data Highlighted at ESMO 2022
    CEL-SCI Multikine Phase 3 Data Highlighted at ESMO 2022
    • September 10, 2022
  • Mayo-Clinic-Gene-Accelerator
    Mayo Clinic, Hibiscus BioVentures, and Innoforce Announce Mayflower Cell and Gene Therapy Accelerator
    • August 31, 2022
Categories
  • BioTech CEO Interviews (4)
  • Biotech Info (1)
  • Biotech News (44)
  • Uncategorized (2)
Author
Hello, I’m
BioTech Health X
Follow
BioTech Health X
Designed & Developed by BioTech Health X
  • Our Contributors
  • List of Modern Life Science Technologies
  • Contact Us

Subscribe to
Our Updates

Back to top